Olutasidenib
- Generic Name
- Olutasidenib
- Brand Names
- Rezlidhia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H15ClN4O2
- CAS Number
- 1887014-12-1
- Unique Ingredient Identifier
- 0T4IMT8S5Z
- Background
Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. IDH1 mutations are common in different types of cancer, ...
- Indication
Olutasidenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
- Associated Conditions
- Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)
- Associated Therapies
- -
Rigel enrols first participant in Phase Ib/II AML treatment regimen trial
Rigel Pharmaceuticals enrolls first subject in Phase Ib/II trial of REZLIDHIA (olutasidenib) combined with decitabine and venetoclax for mIDH1 AML, sponsored by MD Anderson. The trial aims to establish safety and recommended Phase II dose, followed by assessing complete remission rate in 60 patients. Rigel and MD Anderson's strategic alliance will explore olutasidenib's potential in various haematologic neoplasms and single-agent use in lower-risk MDS and CCUS.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath